Latest FDA Fast Track Development Program Stories
EWING, N.J., Jan. 20, 2015 /PRNewswire/ -- Celator Pharmaceuticals, Inc.
Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received fast track designation for ABSSSI (acute bacterial skin and skin structure infections) LAUSANNE, Switzerland,
In May, the website for mesothelioma patients and their families reported on the first mesothelioma patient accepted into a U.K.
TEL AVIV, Israel, Sept. 23, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.
Significant company milestones include completion of the Phase 2 PUNCH(TM) CD clinical trial and FDA designation of RBX2660 as Orphan Drug and Fast Track ROSEVILLE, Minn., Aug 4, 2014
Urges FDA to Move Quickly with Final Approval of Eteplirsen WASHINGTON, April 21, 2014 /PRNewswire/ -- The Race to Yes campaign today lauded drug maker Sarepta on its plans to move
Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials Reston, Virginia (PRWEB) March 18, 2014 Aptiv Solutions, a global
EPI-743 in two phase 2 development studies for Friedreich's ataxia MOUNTAIN VIEW, Calif., March 17, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the United States